|Last Price||Today's Change||52-Week Range||Trading Volume|
|57.60||0.09 (+0.16%)||52.49 - 63.62||7.9 million (Below Avg)|
Market data as of 4:04PM 04/24/15. Quotes are delayed by at least 15 min.
Merck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
04/24/2015 1:00 AM ET